|
Volumn 23, Issue 27, 2005, Pages 6807-6809
|
The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer [16]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANASTROZOLE;
AROMATASE INHIBITOR;
ESTROGEN RECEPTOR;
EXEMESTANE;
LETROZOLE;
PROGESTERONE RECEPTOR;
TAMOXIFEN;
ANTINEOPLASTIC AGENT;
BREAST CANCER;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONSENSUS DEVELOPMENT;
COST BENEFIT ANALYSIS;
DISEASE FREE SURVIVAL;
DRUG DOSE SEQUENCE;
FEMALE;
HORMONAL THERAPY;
HUMAN;
LETTER;
POSTMENOPAUSE;
PRIORITY JOURNAL;
PROGNOSIS;
ADJUVANT CHEMOTHERAPY;
AGED;
BREAST TUMOR;
CANCER STAGING;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
METHODOLOGY;
MIDDLE AGED;
MORTALITY;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
SEGMENTAL MASTECTOMY;
SURVIVAL;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AROMATASE INHIBITORS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
MASTECTOMY, SEGMENTAL;
MIDDLE AGED;
NEOPLASM STAGING;
POSTMENOPAUSE;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
RECEPTORS, ESTROGEN;
RISK ASSESSMENT;
SURVIVAL ANALYSIS;
TAMOXIFEN;
|
EID: 27244432204
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.02.3952 Document Type: Letter |
Times cited : (3)
|
References (5)
|